Loading...
•
Sep 30, 2020
Collegium Q3 2020 Earnings Report
Reported record net income, generated meaningful cash flow from operations and paid down debt.
Key Takeaways
Collegium Pharmaceutical reported strong Q3 2020 results, achieving record net income of $11.3 million and generating $34.2 million in cash flow from operations. The company also strengthened formulary access for Xtampza ER and reached a settlement with Teva regarding patent litigation.
Reported record net income in Q3 2020.
Generated $34.2 million in cash flow from operations.
Strengthened formulary access for Xtampza ER, including an exclusive national Medicare Part D win.
Reached a settlement with Teva Pharmaceutical resolving patent litigation.
Revenue by Segment
Forward Guidance
The company has not provided a reconciliation of its full-year 2020 guidance for non-GAAP adjusted income to the most directly comparable forward-looking GAAP measure because it is unable to predict, without unreasonable efforts, the timing and amount of items that would be included such a reconciliation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...